Kanya Rajangam, MD, PhD, NKarta Therapeutics, South San Francisco, CA, gives an update of current advancements in allogeneic natural killer (NK) cell therapies. Addition of membrane-bound IL-15 has enabled NK cells to be active for longer, enhancing efficacy when administered in patients. Whilst NK cells are more difficult to cryopreserve compared to chimeric antigen receptor (CAR) T-cells, improvements in cryopreservation techniques have allowed multi-center clinical trials to be successfully conducted. This interview took place at Meeting on the Mesa 2021.